Management of Microscopic Hematuria

Initial Evaluation and Risk Stratification

The American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guidelines recommend risk stratification and urologic evaluation for patients with 11-20 RBC/HPF, as this level of hematuria places them in at least the intermediate-risk category 1
Verify true microscopic hematuria (≥3 RBC/HPF) on a properly collected clean-catch midstream specimen, according to the AUA/SUFU guidelines 2
Rule out urinary tract infection by obtaining urine culture, and if positive, treat appropriately and repeat urinalysis 6 weeks after treatment completion to confirm resolution, as recommended by the AUA/SUFU guidelines 2
Exclude menstruation in women by repeating urinalysis 48 hours after cessation of menses, as suggested by the AUA/SUFU guidelines 2, 3

The AUA/SUFU guidelines categorize patients with 11-20 RBC/HPF as intermediate-risk, with additional risk factors determining the final risk category 1, 2
High-risk features include age ≥60 years, smoking history >30 pack-years, history of gross hematuria, occupational exposure to chemicals/dyes, and history of pelvic irradiation, according to the AUA/SUFU guidelines 1, 2, 4
Intermediate-risk features include age 50-59 years (women) or 40-59 years (men), smoking history 10-30 pack-years, 11-25 RBC/HPF on single urinalysis, and irritative voiding symptoms, as defined by the AUA/SUFU guidelines 1, 2
Low-risk features include age <50 years (women) or <40 years (men), never smoker or <10 pack-years, and no additional risk factors for urothelial cancer, according to the AUA/SUFU guidelines 1, 2

For high-risk patients, the AUA/SUFU guidelines recommend cystoscopy, multiphasic CT urography, serum creatinine, and voided urine cytology 2, 4
For intermediate-risk patients, the AUA/SUFU guidelines suggest shared decision-making regarding cystoscopy and urinary tract imaging, and assessment for glomerular disease indicators 1, 2
For low-risk patients, the AUA/SUFU guidelines recommend repeat urinalysis in 6 months or proceeding with evaluation based on patient preference 1, 2

Examine urinary sediment for dysmorphic RBCs (>80% suggests glomerular origin), red cell casts (pathognomonic for glomerular disease), significant proteinuria (>500 mg/24 hours), and elevated serum creatinine, as recommended by the AUA/SUFU guidelines 2, 4

Repeat urinalysis at 6, 12, 24, and 36 months if complete workup is negative but hematuria persists, and monitor blood pressure at each visit, according to the AUA/SUFU guidelines 2, 4
Consider repeat cystoscopy and imaging within 3-5 years for persistent or recurrent hematuria, particularly in high-risk populations, as suggested by the AUA/SUFU guidelines 2
Immediate re-evaluation is required if gross hematuria develops, significant increase in degree of microscopic hematuria, new urologic symptoms appear, or development of hypertension, proteinuria, or evidence of glomerular bleeding, according to the AUA/SUFU guidelines 1, 2, 4